What if the key to fighting a devastating disease like ALS lies in the tiniest power plants inside our nerve cells? A groundbreaking study from Stockholm University and the UK Dementia Research Institute at King’s College London has uncovered a surprising clue about amyotrophic lateral sclerosis (ALS), revealing that problems in the energy factories of nerve cells—called mitochondria—kick in early, before other signs of the disease show up. Published in Nature Communications, this discovery could be a game-changer for understanding and treating this brutal condition.
ALS, a ruthless disease that destroys motor neurons (the nerve cells that control your muscles), leads to muscle breakdown and, sadly, is often fatal. While most cases pop up out of the blue, 10-20% are tied to specific gene mutations. Until now, scientists weren’t sure if these mutations all caused ALS the same way or why some nerve cells get hit hard while others hold up. Enter Dr. Eva Hedlund and Dr. Marc-David Ruepp, who led a team using cutting-edge CRISPR gene-editing and stem cell tech to dig into this mystery.
Here’s how they did it: they took human stem cells (iPS cells) and used CRISPR to add different ALS-causing mutations. From those, they grew motor neurons—the cells that die in ALS—and interneurons, which are tougher and resist the disease. Then, with a high-tech method called single-cell RNA sequencing, they peeked inside each cell to see what was going on. What they found was a common “ALS signature” in motor neurons across all mutations, showing up super early. The culprit? Trouble in the mitochondria and how they’re shuttled to the nerve cells’ long extensions, where they’re needed to power communication with muscles.
“We saw these energy factory issues right after the motor neurons formed,” Hedlund explains. “It’s like the cells are running on empty before the disease even gets rolling.” This was a shock because scientists used to think the first problem was mutated proteins piling up in the wrong parts of the cell (a process called mislocalization). But this study flipped that idea on its head, showing that the real trouble often comes from a toxic new behavior in these mutated proteins, not just a loss of their normal function.
Another big find? The transport system for mitochondria—think of them as tiny battery packs—gets jammed up in ALS, leaving the nerve cells’ extensions starved for energy. “Without enough juice, these cells can’t talk to muscles properly,” says Ruepp. This early glitch, shared across different ALS mutations, suggests a universal target for future drugs, no matter what’s causing the disease.
The team’s discoveries are a big deal because they open the door to early treatments. “We’re now laser-focused on figuring out why these motor neurons are so vulnerable and how these energy issues mess with their ability to connect with muscles,” Hedlund says. Their work could lead to therapies that hit ALS before it takes hold, potentially saving lives.
For now, this study—led by first author Dr. Christoph Schweingruber—offers hope that by targeting these early cellular hiccups, we might one day stop ALS in its tracks. It’s a reminder that even in the face of a tough disease, science is out here swinging, finding new ways to fight back.
This research was supported by Stockholm University and the UK DRI, bringing us closer to cracking ALS wide open.